This article may contain commentary
which reflects the author’s opinion.
A federal appeals court has temporarily blocked a Biden-era rule allowing abortion pills to be distributed by mail, a decision that could significantly affect access to medication abortion across the United States as broader legal challenges continue to unfold.
In a unanimous ruling, a three-judge panel of the U.S. Court of Appeals for the Fifth Circuit sided with the state of Louisiana, finding it was likely to succeed in its challenge to a 2023 regulation issued by the U.S. Food and Drug Administration. That rule had removed a long-standing requirement that the abortion drug mifepristone be dispensed in person, allowing patients to receive it through the mail following telehealth consultations.
The court’s decision is temporary and will remain in place while the broader case proceeds, but it marks the first time a federal court has moved to roll back expanded access to the drug in recent years.
Advertisement
Mifepristone is one of two medications commonly used in abortion care, typically followed by misoprostol, and is approved for use during the first 10 weeks of pregnancy. According to research cited in court filings, medication abortion now accounts for a majority of abortions in the U.S., with a growing share of prescriptions delivered through telehealth services rather than in-person visits.
Advertisement
The legal challenge stems from a lawsuit filed by Louisiana, where officials argued that the FDA failed to adequately consider potential risks when it relaxed dispensing requirements. Those concerns include rare but serious complications such as hemorrhaging or infection. In its ruling, the appeals court questioned whether the agency had sufficiently justified its decision to ease restrictions.
Circuit Judge Stuart Kyle Duncan wrote that the FDA’s “progressive relaxation” of safeguards around the drug “likely lacked a basis in data and scientific literature,” signaling skepticism toward the regulatory changes made in recent years.
The Biden administration had defended the rule, maintaining that mifepristone is safe and effective based on extensive clinical data. Federal health officials have pointed to studies showing serious adverse events occur in a small fraction of cases, generally cited as less than 1 percent.
The companies that manufacture and distribute the drug—Danco Laboratories, which produces the brand-name version Mifeprex, and GenBioPro, which makes a generic version—have intervened in the case to support the FDA’s position. Both companies have argued that restricting access would disrupt care and harm patients who rely on medication abortion, particularly in states with limited clinic availability.
The ruling comes against the backdrop of a broader legal and political fight over abortion access following the Supreme Court’s 2022 decision in Dobbs v. Jackson Women’s Health Organization, which ended federal constitutional protections for abortion and returned regulatory authority to the states. Since then, nearly half of U.S. states have enacted bans or severe restrictions, contributing to increased reliance on medication abortion and telehealth services.
In states where abortion remains legal, telehealth prescriptions have become a key pathway for access. Some estimates suggest that fewer than 2 percent of abortion pill prescriptions in those states are now filled in person.
The legal landscape is further complicated by conflicting state laws. Some states, including Louisiana and Texas, have pursued legal action against out-of-state providers who prescribe abortion medication to their residents, testing so-called “shield laws” in states like New York and California that are designed to protect providers from such enforcement efforts.
A lower court judge had previously paused Louisiana’s case to allow the Trump administration time to conduct its own review of mifepristone’s safety. However, the appeals court intervened to block the mail-order provision in the meantime, indicating the issue warrants immediate consideration.
Additional lawsuits filed by other Republican-led states are also moving through the courts, challenging not only the 2023 rule but the FDA’s original approval of mifepristone more than two decades ago. The outcome of these cases could have far-reaching implications for how the drug is regulated and accessed nationwide.
